Diarylsulfonylureas--a new class of antitumor agents.
Diarylsulfonylureas (DSU) represent a new class of antitumor agents. DSU exhibit an exceptionally broad spectrum of activity against solid tumors. They show different toxicity to conventional anticancer agents and exhibit no cross-resistance with existing anticancer agents. In particular they have an unknown, but unique, potentially novel mechanism of action. Sulofenur is the first DSU to progress to clinical evaluation. The dose-limiting toxicity in humans is anemia and methemoglobinemia. Recently, DSU with novel structural features have also been reported to exhibit potent antitumor activity, demonstrating structural diversity of DSU antitumor agents.
Guan
X
X
Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Box 2202C, Brookings, SD 57007-0099, USA. GUANX@MG.sdstate.edu